Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02930200 · ClinicalTrials.gov registry record · NA
Clinical Trial of an Automated Smartphone Based Smoking Cessation Treatment
A NA study, sponsored by University of Oklahoma.
- Completed
- Registry status
- NA
- Development phase
- 98
- Enrollment target
NCT02930200: Completed NA study, sponsored by University of Oklahoma.
NCT02930200 is a NA study that has completed, run by University of Oklahoma. The registered enrollment target is 98 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02930200, a NA study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- NA
- Development phase
- 98 participants
- Enrollment target
Study Summary
The primary long-term objective of this research is to reduce smoking relapse through the use of automated mobile smoking cessation interventions that tailor content (e.g., treatment messages/materials) in real-time based upon currently present symptoms. The primary short-term objective of this pilot study is to determine the initial utility of a novel smartphone based smoking cessation intervention compared with standard in-person smoking cessation clinic care and the free National Cancer Institute (NCI) QuitGuide smoking cessation application. The current pilot study is a 3 armed randomized clinical trial that aims to determine the initial utility of a novel smartphone based smoking cessation intervention compared with standard in-person smoking cessation clinic care and the free NCI QuitGuide smoking cessation application.
Primary Outcome
Biochemically-verified smoking cessation will be verified if the participants have a CO level of \< 10 on the quit day and \< 6 ppm at all subsequent post-quit visits
Interventions
- BEHAVIORAL Treatment as Usual
- BEHAVIORAL QuitGuide
- BEHAVIORAL Smart-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2017-05-30 |
| Est. Completion | 2018-11-01 |
| Phase | NA |
What the finished NCT02930200 record still lists
NCT02930200 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Treatment as Usual is the first listed.
NCT02930200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02930200 about?
NCT02930200 is a clinical study titled "Clinical Trial of an Automated Smartphone Based Smoking Cessation Treatment". The primary long-term objective of this research is to reduce smoking relapse through the use of automated mobile smoking cessation interventions that tailor content (e.g., treatment messages/materials) in real-time based upon currently present symptoms. The primary short-term objective of this pilo...
What is the current status of trial NCT02930200?
This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2017-05-30. Estimated completion is 2018-11-01.
What interventions are being tested in trial NCT02930200?
The interventions under investigation include: Treatment as Usual (BEHAVIORAL), QuitGuide (BEHAVIORAL), Smart-T (BEHAVIORAL).
Who is sponsoring clinical trial NCT02930200?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02930200's enrollment target sits among peer trials
98 922nd of 2000 higher than 1,078 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI